Like a seed needs soil to grow and flourish, a tumor relies on its environment to grow and spread in the body -- something the Vanderbilt-Ingram Cancer Center will be exploring more closely with the help of a new $6.5 million grant from the National Cancer Institute (NCI).

Jennifer A. Pietenpol, Ph.D., has been selected to lead the Vanderbilt-Ingram Cancer Center as interim director.

Raymond DuBois Jr., M.D., Ph.D., will leave his position as director of the Vanderbilt-Ingram Cancer Center later this year to return to his native Texas as provost and executive vice president of academic affairs at M.D. Anderson Cancer Center in Houston.

The Vanderbilt-Ingram Cancer Center and AstraZeneca have developed a master scientific agreement to streamline and integrate collaborations in basic, translational and clinical cancer research, officials with the company and cancer center announced today.

When 24-year-old Charles Dougherty checks into Vanderbilt-Ingram Cancer Center tomorrow, he'll be preparing for a treatment that has never been performed before in an adult patient in Nashville, and will be only the second case in Tennessee history.

Initial Results of the Study of Tamoxifen and Raloxifene or STAR, released today revealed the osteoporosis drug raloxifene has been proved to be as effective as tamoxifen in preventing invasive breast cancer.

Researchers at the Vanderbilt-Ingram Cancer Center are studying whether exercise can help curb memory and cognitive problems experienced by many cancer survivors following chemotherapy.